Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
Background Post‐marketing pharmacovigilance data are scant on the safety of Covid‐19 vaccines among people with previous SARS‐CoV‐2 infection compared with ordinary vaccine recipients. We compared the post‐vaccination adverse events of special interests (AESI), accident and emergency room (A&E)...
Gespeichert in:
Veröffentlicht in: | Journal of internal medicine 2022-06, Vol.291 (6), p.864-869 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Post‐marketing pharmacovigilance data are scant on the safety of Covid‐19 vaccines among people with previous SARS‐CoV‐2 infection compared with ordinary vaccine recipients. We compared the post‐vaccination adverse events of special interests (AESI), accident and emergency room (A&E) visit, and hospitalization between these two groups.
Methods
We conducted a retrospective cohort study using a territory‐wide public healthcare database with population‐based vaccination records in Hong Kong.
Results
In total, 3922 vaccine recipients with previous SARS‑CoV‑2 infection and 1,137,583 vaccine recipients without previous SARS‑CoV‑2 infection were included. No significant association was observed between previous SARS‑CoV‑2 infection and AESI or hospitalization. Previous SARS‑CoV‑2 infection was significantly associated with a lower risk of A&E visit (CoronaVac: hazard ratios [HR] = 0.56, 95% confidence intervals [CI]: 0.32–0.99; Comirnaty: HR = 0.62, 95% CI: 0.47–0.82).
Conclusion
No safety signal of Covid‐19 vaccination was detected from the comparison between vaccine recipients with previous SARS‐CoV‐2 infection and those without infection. |
---|---|
ISSN: | 0954-6820 1365-2796 |
DOI: | 10.1111/joim.13453 |